Skip to content
Screener

NovoCure NVCR PP&E (Net)

PP&E (Net) at other companies

Boston Scientific logo
Boston ScientificBSX
$4.06B+19.9%
Medtronic logo
MedtronicMDT
$7.42B+8.5%
Nuvation Bio logo
Nuvation BioNUVB
$715K+16.3%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$131.46M+7.3%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$6.38M-15.4%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$27.28M+16.6%

Segments

By geography

See full
United States$65.67M
Switzerland$48.13M
Israel$14.06M

Other financials

Income statement

See full
Revenue$183.6M+15.6%
Gross profit$142.5M+21.4%
Operating income-$10.6M+73.3%
Net income-$15.7M+61.0%
EPS (diluted)-$0.13+63.9%

Balance sheet

See full
Cash & equivalents$93.7M-37.4%
Total debt$37.5M-12.4%
Total equity$338.1M-3.2%
Total assets$795.2M-36.2%

Cash flow

See full
Operating cash flow$8.1M+151%
CapEx$6.9M+26.1%
Free cash flow$1.2M+106%

Valuation

See full
Market cap$1.91B+56.6%
Enterprise value$1.85B+66.6%
P/S2.7×+0.8×

Profitability

See full
Gross margin76.1%-0.3pp
Operating margin-22.1%-3.6pp
Net margin-21.2%-3.8pp
FCF margin-3.6%-1.5pp

Returns & leverage

See full
Return on equity-43.2%-4.0pp
Debt / equity0.1×0.0×
Current ratio2.9×+1.4×

Where this comes from

Reported directly by NovoCure in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The source filing: NovoCure’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 6:59 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001645113-26-000062
Line itemJune 30,2026December 31, 2025
Inventories42,22441,111
Total current assets638,521646,731
LONG-TERM ASSETS:
Property and equipment, net75,36977,606
Field equipment, net26,58222,066
Right-of-use assets43,78947,327
Other long-term assets10,93010,596
Total long-term assets156,670157,595

Item 1. Financial Statements

FAQ

What is NovoCure's PP&E (net)?
NovoCure (NVCR) reported PP&E (net) of $75.37M in Q2 2026.
How has NovoCure's PP&E (net) changed year-over-year?
NovoCure's PP&E (net) decreased by 6.2% year-over-year, from $80.33M to $75.37M.
What is the long-term trend for NovoCure's PP&E (net)?
Over 5 years (2020 to 2025), NovoCure's PP&E (net) has grown at a 46.8% compound annual growth rate (CAGR), from $11.4M to $77.61M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.

Ask your AI about NovoCure's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude